1. This study has evaluated the effect of somatostatin (0-1 or 3 ,ug/ml) on the release of thyroxine, 3,5,3'-tri-iodothyronine and 3,3',5'-tri-iodothyronine from perfused thyroid lobes.
Introduction
Somatostatin was initially hiscovered in the hypothalamus and characterized as an inhibitor of growth hormone secretion. However, it has subsequently been found to have an inhibitory effect on the secretion of several other peptide hormones, both pituitary and non-pituitary. Further, immunoreactive somatostatin has been demonstrated in Correspondence: Dr P. Laurberg, Second University Clinic of Internal Medicine, Komrnunehospitalet, DK-8000 Aarhus C, Denmark. several non-pituitary tissues including the thyroid (Hokfelt, Efendi6, Hellerstrom, Johansson, Luft & Arimura, 1975; Parsons, Erlandsen, Hegre, McEvoy & Elde, 1976; Van Noorden, Polak & Pearse, 1977; Yamada, Ito, Matsubara & Kobayashi, 1977; Kronheim, Berelowitz & Pimstone, 1976) .
Controversy exists on whether somatostatin also has a direct effect on thyroid hormone secretion (AhrCn, Hedner, Melander & Westgren, 1977; Loos, Raptis, Birk Escobar-Jimenez, Meyer, Rothenbuchner & Pfeiffer, 1978; Ahrkn, Ericsson, Hedner, Ingemansson & Westgren, 1978; Faber, Gormsen, Friis, Kirkegaard, Birk, Lauridsen, Nerup, Rogowski & Siersbaek-Nielsen, 1977) . The aim of the present study was to elucidate this problem by using a sensitive and precise thyroidperfusion model.
Material and methods
Thyroid perfusions were performed in six mongrel dogs weighing 22-30 kg. Since the two thyroid lobes are totally separate in dogs, both lobes could be perfused independently, one acting as a control of the other. The technique has been described in detail (Laurberg, 1976 (Laurberg, , 1977 . Once-through perfusions were performed in situ with a synthetic medium. The flow rate for each thyroid lobe was kept at 0.63 ml/min. The duration of the perfusions was 200 min. Cyclic somatostatin [O-1 ,ug/ml (61 nmol/l) In different experiments somatostatin was administered alternately to the left and right thyroid lobe. TSH was added to the perfusion medium in the final concentration. Somatostatin was diluted in NaCl solution (150 mmol/l) to a concentration of 10 or 300 pg/ml. This stock solution of somatostatin was pumped into the medium through a cannula penetrating a rubber membrane on the afferent catheter, at a rate of 6.3 pl/min. Mixing was obtained in a small volume drop-chamber introduced after the addition of somatostatin. It was ascertained by dye-ddution studies that somatostatin was evenly distributed in the perfused thyroid lobe. Somatostatin was almost quantitatively recovered in the effluent when measured by radioimmunoassay (measurements of somatostatin were performed by Dr Hans Orskov).
T,, T, and rT, in thyroid effluent and pronase hydrolysate of thyroid tissue were measured by radioimmunoassays (Weeke & Orskov, 1975 Laurberg, 1978a) . All samples from one experiment were measured in triplicate in one assay.
Student's t-test for paired comparisons was applied for statistical analyses, a 5% limit of significance being used.
Results
The influence of 0.1 pg of somatostatin/ml on thyroid iodothyronine secretion was investigated in two experiments. Somatostatin infusion did not influence the TSH-induced release of T,. In the first experiment the basal T, release before somatostatin was: from the control lobe, 25 nmol/l; from the somatostatin lobe, 23 nmol/l; after 140 min of somatostatin infusion and 100 min of TSH at 10 punitdml, T, in emuent from the control lobe was 129 nmol/l and from the somatostatin lobe 108 nmol/l. In experiment 2 the basal T, release from the control lobe was 26 nmol/l and from the somatostatin lobe 28 nmol/l; after somatostatin and TSH, T, release from the control lobe was 150 nmol/l and from the somatostatin lobe 176 nmol/l. The release of T, and rT, was also nearly identical from the two lobes.
To exclude that a lack of effect could be due to the use of insufficiently high concentrations of somatostatin in this system in vitro and to exceed any possible concentration of somatostatin invol- ved in a possible paracrine regulation of thyroid hormone secretion, subsequent experiments were performed with the higher concentration of 3 pg of somatostatin/ml. The mean T, concentrations in effluent from four thyroid lobes receiving 3 pg of somatostatin/ml and four control lobes appear in Fig. 1 . Infusion of somatostatin in unstimulated thyroid lobes did not induce any alteration in secretion rate. Bovine TSH (10 ,uunits/ml) stimulated the release of T,. There was no difference in latency period before response or in shape of the curves in lobes receiving somatostatin and control lobes. Neither total nor fractional increase in T, release was signifiantly altered by somatostatin infusion. Ratios of T,/T, and T,/rT, in thyroid emuent and in pronase hydrolysate of the thyroid lobes in the four experiments where 3 pg of somatostatin/ml was employed are given in Table 1 . Both T,/T, and T,/rT, were higher in thyroid hydrolysate than in thyroid effluent. Infusion of somatostatin did not alter the T,/T, or T,/rT, ratios in effluent from unstimulated or TSH-stimulated thyroid lobes.
Discussion
Previous studies employing this preparation have revealed that a considerable part of the T, and rT, secreted originates from T, monodeiodinated during the secretion (Laurberg, 1978b) . However, the fraction of T, disappearing during secretion is small since inhibition of intrathyroidal iodothyronine deiodination does not induce major alterations in T, secretion (Laurberg, 1978b) . Thus T, in thyroid eluent can be considered as a measure of overall thyroid secretory activity, and the difference between the T,/T, and T,/rT3 ratios in thyroid eluent and in the iodothyronine stores in thyroglobulin is a measure of intrathyroidal iodothyronine deiodination. In the present study neither overall thyroid secretory activity nor intrathyroidal iodothyronine deiodinating processes were affected by somatostatin. It is well established that somatostatin affects the pituitary-thyroid system in intact man and animals by suppressing TSH secretion (Snow, Scanlon, Mora, Heath, Hall & Comez-Pan, 1978) . On the other hand, there is some controversy on a possible direct effect of somatostatin on thyroid secretion. Ahrbn et al. (1977) studied the effect of somatostatin on thyroid lZ5I release from mouse thyroids in a modified McKenzie bioassay for thyroid stimulators. It was found that somatostatin reduced the blood lZsI increase in response to TSH, isoprenaline or dibutyryl-cyclic AMP slightly, but statistically significantly.
Loos et al. (1978) reported that somatostatin enhanced thyroid radioiodine uptake after injection of TSH into human subjects, and the appearance of labelled protein bound iodine in serum was inhibited. Further the increase in T, and T, in serum was inhibited slightly. The reasons for the discrepancy in reported results are not obvious. Naturally, some could be due to species differences. However, somatostatin has been demonstrated in parafollicular cells of normal dog thyroids (Yamada et al., 1977) and it can be measured in effluent from the perfused canine thyroid (P. Laurberg & H. Orskov, unpublished work) . Various preparations of somatostatin have been used in the different studies. However, the preparation employed by Ahr6n et al. The preparation of somatostatin used in the present study has proved effective in a number of studies in vivo and in vitro'in our laboratory (Hansen & Lundbaek, 1976) . The relatively short duration of the somatostatin infusion in the present study seems not to be the cause for the difference in results, since all the above-mentioned studies showing an effect of somatostatin on thyroid secretion have been shortterm studies. Our use of bovine TSH for stimulation of thyroid secretion cannot be the cause either, since bovine TSH has been used for stimulation in all studies, and the concentration of TSH used in the present study does not exceed that employed in earlier studies.
The interpretation of experiments in uiuo are difficult, owing to the possibility of alterations in the distribution and deiodination of peripheral iodothyronines. Studies employing measurements of iodothyronines in thyroid venous blood are hampered by the comparatively high basal content of thyroid hormones in blood. Further, alterations in blood flow are difficult to check, especially when vasoactive agents like somatostatin are used. The perfused canine thyroid has proved to be a very sensitive and precise preparation for monitoring small alterations both in basal and stimulated states of iodothyronine release as well as alterations in the relative ratios between the individual iodothyronines in thyroid secretion. These advantages are primarily due to the use of a synthetic hormonefree medium for once-through perfusion, and the strict control of perfusion flow.
The results of the present study obtained under well-defined and controlled conditions lend no support to the idea that intrathyroidal somatostatin modifies thyroidal secretion of iodothyronines. However, since treatment with somatostatin in uiuo has been shown by some investigators to have an effect on thyroid secretion, it is possible that infusion of somatostatin can have some indirect effect on thyroid secretion.
